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Like most human neoplasm, breast cancer has aberrations in
signal transduction elements that can lead to increased prolifer-
ative potential, apoptosis inhibition, tissue invasion and metasta-
sis. Due to the high heterogeneity of this tumor, currently, no
markers are clearly associated with the insurgence of breast can-
cer, as well as with its progression from in situ lesion to invasive
carcinoma. We have recently demonstrated an altered expression
of the b2 isoform of the phosphoinositide-dependent phospholi-
pase C (PLC) in invasive breast tumors with different histopath-
ological features. In primary breast tumor cells, elevated amounts
of this protein are closely correlated with a poor prognosis of
patients with mammary carcinoma, suggesting that PLC-b2
may be involved in the development and worsening of the malig-
nant phenotype. Here we demonstrate that PLC-b2 may improve
some malignant characteristics of tumor cells, like motility and
invasion capability, but it fails to induce tumorigenesis in non-
transformed breast-derived cells. We also report that, compared
with the G0/G1 phases of the cell cycle, the cells in S/G2/M phases
show high PLC-b2 expressions that reach the greatest levels dur-
ing the late mitotic stages. In addition, even if unable to modify the
proliferation rate and the expression of cell cycle-related enzymes
of malignant cells, PLC-b2 may promote the G2/M progression, a
critical event in cancer evolution. Since phosphoinositides, sub-
strates of PLC, are involved in regulating cytoskeleton architec-
ture, PLC-b2 in breast tumor cellsmaymediate themodification of
cell shape that characterizes cell division,motility and invasion.On
the basis of these data, PLC-b2may constitute amolecularmarker
of breast tumor cells able to monitor the progression to invasive
cancers and a target for novel therapeutic breast cancer strategies.
Introduction
Phosphoinositide-specific phospholipase C (PLC) is one of the key
enzymes in the metabolism of inositol lipids. It plays a crucial role in
multiple transmembrane signal transduction pathways that regulate
numerous cell processes, including proliferation and motility (1). At
present, 13 mammalian PLC isoforms have been reported and char-
acterized, divided in the five subfamilies b, c, d, e and f. They differ in
structure and activation mechanism and show expression patterns that
reflect the function identified for each isozyme in the diverse tissues
(1–3).
The different PLC isozymes show discrete localization in both
cytoplasm and nuclei of a number of cell types, in which they regulate
events dependent on the inositol lipid cycle. In particular, the
modifications of the phosphoinositide pool, as a consequence of
PLC activity, have been reported to be involved in actin cytoskeleton
reorganization, chromatin remodeling and gene transcription (4,5).
Altered expression and activity of specific PLC isoforms are com-
monly detected in a variety of different human cancers and are often
associated with the appearance and progression of tumoral pheno-
types. For instance, b isozymes are frequently associated to hemato-
poietic malignancies and neuroendocrine tumors (6–9). Members of
the c subfamily have been found to be up-regulated in neoplastic
leukocytes (10) and in colon carcinoma, where they may play a role
in carcinogenesis (11). In addition, PLC-d isozymes have been found
to be involved in the neoplastic evolution of gastric mucosa and
hepatic cells (12,13).
While a role in promoting cell cycle progression by targeting
cyclin–cyclin kinase complexes has been reported for PLC-b1 (14),
a general role of PLC in regulating tumorigenic features of cancer-
derived cells has been coupled to its capability to modulate the local
levels of phosphoinositides. A central role in this context seems to be
played by the preferred PLC substrate PtdIns (4,5)P2 that, in addition
to be a precursor of the second messengers inositol 1,4,5-trisphosphate
and diacylglycerol, is a substrate for Phosphoinositide 3-kinase. PtdIns
(4,5)P2 may directly influence actin cytoskeleton organization, which
is deregulated in a number of human tumors (15).
Evidence from different groups indicate that in breast cancer, like
in most human neoplasms, some PLC isoforms show altered expres-
sions, even if their involvement in neoplastic transformation is cur-
rently poorly understood. For instance, a number of data report that
PLC-c1 is over-expressed in breast cancer cells, in which it has a role
in EGFR-driven tumor progression and cell migration (16–18). Also
PLC-d4 was found to be up-regulated in some breast tumors and
its over-expression seems to increase the proliferation rate of low-
tumorigenic breast cancer cells (19). Recently, we have demonstrated
that PLC-b2 is over-expressed in a large majority of breast tumors
and that its amount correlates with a poor clinical outcome, consti-
tuting a molecular marker of breast cancer severity (20).
On the basis of our previous data, the aim of this work was to
establish if PLC-b2 is directly involved in the carcinogenic steps of
promotion and progression of human mammary neoplasia. In this
study, we demonstrate that, even though PLC-b2 fails to induce tu-
morigenesis in non-transformed breast-derived cells, it has a major
role in promoting migration. We also provide evidence that PLC-b2
induces transition from G0/G1 to S/G2/M phases of the cell cycle,
which appears to be a critical event in cancer progression, without
affecting cell cycle-associated enzymes. PLC-b2, by modifying the
phosphoinositide pool, may then be responsible for inositol lipid-
related modifications of cytoskeleton architecture that occur during
division, motility and invasion of tumor cells.
Materials and methods
Immunohistochemical analysis of breast tissues
Formalin-fixed and paraffin-embedded samples from normal breast and pri-
mary infiltrating breast cancers with different histological grade, estimated by
using Elston and Ellis criteria (21), were obtained from the Department of
Experimental and Diagnostic Medicine of University of Ferrara (Ferrara,
Italy), after informed consent according to the Helsinki declaration of 1975.
All patients were treated with surgery for primary breast cancer and none of
them received neoadjuvant treatment or had distant metastasis at the time of
primary surgery.
For analysis of PLC-b2 expression, tissue sections were deparaffinized by
means of the clearing agent Bioclear (Bio-Optica, Milan, Italy), rehydrated in
distilled water through graded alcohols (ethanol 100, 95 and 70%, respec-
tively) and subjected to immunohistochemical analysis with an anti-PLC-b2
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) using the Ultraystain
Polyvalent-HRP immunostaining kit (YLEM, Rome, Italy). In particular, the
Abbreviations: MFI, mean fluorescent intensity; PBS, phosphate-buffered
saline; PI, propidium iodide; PLC, phospholipase C.
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slides were incubated in 3% (vol/vols) H2O2 and the endogenous peroxidase
was blocked with Super Block reagent (YLEM). The samples were then in-
cubated at room temperature for 90 min with anti-PLC-b2 rabbit polyclonal
IgG (1:100 in 10 mM Tris–HCl, pH 8.0, 150 mM NaCl). The slides were fur-
ther incubated for 10 min at room temperature with anti-polyvalent biotinylated
antibody and, after rinsing in the same buffer, streptavidin–horseradish perox-
idase was applied for 10 min. The antibody localization was detected by the
addition of substrate/chromogen mix (AEC Cromogeno Kit, YLEM) and the
sections were finally counterstained with Mayer’s hemallume solution and
rinsed for 10 min in tap water. Negative controls were obtained by omitting
the primary antibody. Each tissue sample, after hybridization with the anti-
PLC-b2 antibody, was analyzed using an optical microscope (Carl Zeiss
Axiophot 100, Oberlochen, Germany).
Breast-derived cell lines
The breast cancer-derived cell lines MDA-MB-231 and MCF7 and the non-
transformed MCF10A cells were purchased from the American Type Culture
Collection (Rockville, MD). The low-tumorigenic BT-474 cell line was from
ICLC (Genova, Italy). MDA-MB-231 and MCF7 were grown in Dulbecco’s
modified Eagle’s medium (Gibco-BRL, Grand Island, NY) supplemented
with 10% fetal calf serum (Gibco-BRL). MCF10A cells were cultured in
Dulbecco’s modified Eagle’s medium and Ham’s F-12 medium (1:1, vol/vols)
containing 10 lg/ml bovine insulin, 100 ng/ml cholera toxin, 0.5 lg/ml hy-
drocortisone, 20 ng/ml recombinant human epidermal growth factor and 10%
horse serum. BT-474 were maintained in RPMI 1640 growth medium (Gibco-
BRL) supplemented with 10% fetal calf serum, 1 mM Na pyruvate and
0.01 mg/ml bovine insulin in 5% CO2 atmosphere. Subconfluent cells were
counted daily and cell morphology was evaluated using an inverted phase-
contrast microscope (Nikon, Melville, NY).
Serum-starved cells were obtained by culturing the different cell lines for
48 h in the presence of 1% fetal calf serum.
Immunochemical analysis
Cells were harvested when 70–80% confluent, washed twice with cold phos-
phate-buffered saline (PBS) containing 1mM Na3VO4 and lysed with a buffer
containing 50 mM Tris–HCl, pH 7.4, 1% Nonidet P-40, 0.25% sodium deox-
ycholate, 150 mM NaCl, 1 mM ethylenglycol-bis (b-aminoethylethen)-N, N#-
tetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1 lg/ml each Aprotinin
and Leupeptin and 1 mM Na3VO4 (all from Calbiochem, La Jolla, CA).
For immunoprecipitation experiments, after 1 h at 4C, the insoluble mate-
rials were removed and supernatant (1 mg protein) was incubated with a poly-
clonal antibody against human PLC-b2, followed by precipitation with protein
A-Sepharose, as previously reported (20).
Total lysates (50 lg protein) and immunoprecipitates were resuspended in
Laemmli’s sample buffer, separated on 7.5% polyacrylamide denaturing gels
and blotted to nitrocellulose membranes (Amersham Life Science, Little
Chalfont, UK). The membranes were then incubated with antibodies directed
against PLC-b2 (Santa Cruz) and against cyclin A, cyclin D1, cyclin D3,
CDK4, actin and b-tubulin (Sigma Chemicals, St Louis, MO). The final de-
tection was performed using the Enhanced Chimiluminescence system (Perkin-
Elmer, Boston, MA), according to the manufacturer’s instructions and
densitometric analysis of autoradiograms was performed on the ImageQuant
TL (Amersham Bioscience, Little Chalfont, UK).
RNA interference assay
Specific siRNAs were designed by selecting four target sequences in the cod-
ing region of PLC-b2 mRNA (accession number NM 004573). Sense and
antisense sequences were chemically synthesized by Qiagen S.p.A. (Milan,
Italy). The lyophilized siRNA was dissolved in sterile suspension buffer
(100 mM potassium acetate, 2 mM magnesium acetate, 30 mM Hepes-KOH,
pH 7.4) to obtain a 20 lM solution, and then nucleotides were heated to 90C
for 1 min followed by 1 h at 37C. As a control, non-silencing fluorescein-
labeled duplex siRNA, also purchased from Qiagen, was used.
Transfection was conducted with Lipofectamine 2000 (Invitrogen, Milan,
Italy) in six-well plates according to the manufacter’s specification. In sum-
mary, the day before transfection, cells were trypsinized, counted and seeded at
5 105 cells/well into six-well plates, so that they were 40–45% confluence on
the day of transfection. Lipofectamine 2000, diluted in Opti-MEM I medium
(Gibco-BRL), was supplemented to the RNA mixture and 100 ll of the mixture
were then added to each well. The transfected cells were incubated at 37C in a
CO2 atmosphere for 24–48 h and then subjected to immunochemical analysis.
PLC-b2 over-expression
All cell lines were transfected with plasmids expressing an Enhanced Green
Fluorescent Protein (EGFP)-tagged full-length human PLC-b2. DNA con-
structs were obtained by subcloning the specific fragments into expression
vectors (Pharmacia Biotech, Uppsala, Sweden) in the correct reading frame,
amplifying plasmidic DNA in competent bacteria DH5a (Invitrogen) and ex-
tracting DNA by means of a specific purification kit (Qiagen Plasmid Maxi Kit).
DNAwas supplemented to Lipofectamine 2000 (Invitrogen), diluted in Opti-
MEM I medium and the mixture was then added to each well of the six-well
plate containing 9  105 cells/well (90% confluence). The transfected cells
were incubated for 24–48 h at 37C in a humidified 5% CO2 atmosphere and
then subjected to immunochemical analysis.
Proliferation assay
The analysis of cell proliferation was carried out by performing an MTT
(3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide) colorimetric
assay (Roche, Penzberg, Germany), according to the manufacturer instruc-
tions. Breast-derived cells (2  103) were seeded into microplates (tissue
culture grade, 96 wells, flat bottom), in a final volume of 100 ll culture
medium per well, for overnight incubation at 37C and 5% CO2. Ten micro-
liters of the MTT labeling reagent (final concentration 0.5 mg/ml) were then
added to each well and the microplates were further incubated for 4 h. The
MTT solution was than removed and 100 ll of solubilization solution were
added to each well to dissolve formazan crystals. After an overnight incubation
(37C and 5% CO2), the spectrophotometrical absorbance of the samples was
read with an Anthos 2010 ELISA reader operating at 540 nm (Anthos Labtec
Instruments, Wals Salzburg, Austria).
Chemomigration assay
Cell migration was determined using a 24-transwell migration chamber assay
(Costar, Boddenheim, Germany) equipped with 6.5 mm diameter, 8 lm pore
size polycarbonate inserts. Cell migration was quantified by the number of
cells that were migrated directionally through collagen IV (40 lg/ml)-coated
inserts toward serum as a chemoattractant. Cells (0.5  105) were resuspended
in 100 ll of serum-free medium containing 0.1% bovine serum albumin and
added to the transwell inserts. In all, 600 ll of medium were added to the lower
compartments of the chambers. After 24 h of incubation, cells attached to the
bottom surface of the membrane were fixed and stained with crystal violet.
Non-migrated cells were then removed by wiping with a cotton swab and at
least four random fields of vision were counted for quantification of cell
migration using a light microscope (Carl Zeiss Axiophot 100).
In vitro cell invasion assay
Cell invasion assay was performed according to the protocol from Chemicon
(Tamecula, CA). The Cell Invasion Assay Kit (ECM550) utilizes an Invasion
Chamber, which consists of a 24-well tissue culture plate and 12 cell culture
inserts. The inserts contain an 8 lm pore size polycarbonate membrane, over
which a thin layer of ECMatrix solution is applied (ECM layer occludes the
membrane pores, blocking non-invasive cells from migrating through; in con-
trast, invasive cells migrate through the ECM layer). Cells (0.5 105) in 300 ll
of serum-free media were added to each insert and 500 ll of media containing
10% fetal bovine serum (chemoattractant) was added to the lower chamber.
Chambers were then incubated in 5% CO2 and at 37C for 24–72 h. Non-
invading cells as well as the ECM gel layer were removed using a cotton-tipped
swab. On the contrary, the invasive cells on lower surface of the membrane
were stained by dipping inserts in a staining solution for 20 min; then counted
after observation through a light microscope.
Immunocytochemical analysis
The different breast-derived cell lines, grown onto glass slides, were fixed with
freshly prepared 4% paraformaldehyde (10 min at room temperature), washed
in PBS (5 min) and reacted with the polyclonal anti-PLC-b2 antibody in NET
gel (150 mM NaCl, 5 mM ethylenediaminetetraacetic acid, 50 mM Tris–HCl,
pH 7.4, 0.05% Nonidet P-40, 0.25% carragenin, 0.02% NaN3), for 2 h at room
temperature. Samples were then reacted with a secondary antibody (fluorescein
isothiocyanate-conjugated anti-rabbit IgG; Sigma Chemicals) in NET gel
for 45 min at room temperature. After two washes with NET gel and PBS,
samples were incubated (from 30 s to 5 min) with 0.5 lg/ml 4#,6-diamidino-2-
phenylindole, then washed in PBS, dried with ethanol, mounted in glycerol
containing 1,4-diazabicyclo [2.2.2] octane to retard fading and analyzed with
a fluorescence microscope.
The same experiment was performed in the presence of an anti-PLC-b2
blocking peptide (Santa Cruz) to verify the specificity of the anti-PLC-b2
antibody.
Cytofluorimetric analysis of PLC-b2 expression in the different phases of cell
cycle
For detection of intracellular PLC-b2, 5  105 cells were fixed with 2%
paraformaldehyde for 5 min and then reacted for 30 min with 2 lg/ml anti-
PLC-b2 antibody in NET gel, followed by 30 min with 15 lg/ml fluorescein
isothiocyanate-conjugated anti-rabbit IgG (Jackson Immunoresearch Labora-
tories, West Grove, PA) as secondary antibody.
PLC-b2 in breast tumor malignancy
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Samples were then washed and incubated with 25 lg/ml propidium iodide
(PI) and 0.1 mg/ml RNase (Sigma) in PBS for 30 min. Secondary antibody-
matched controls were used to assess non-specific fluorescence, and after
staining procedures, samples were analyzed with a FACSCalibur flow cytom-
eter (Becton Dickinson, Franklin Lakes, NJ). Analysis of PI fluorescence was
performed with FL-2 detector in a linear mode. Finally, data were analyzed
using CELLQuest 3.2.1.f1 software (Becton Dickinson). Mean fluorescence
intensity (MFI) ratio was calculated as the ratio between the MFI of PLC-
b2-stained and MFI of control-stained cells (secondary antibody alone). The
results were evaluated by using analysis of variance with subsequent compar-
isons by Student’s t-test and with the Mann–Whitney rank-sum test (22).
Cell cycle analysis
The number of cells in each phase of the cell cycle was evaluated by means of
flow cytometry after PI staining of ethanol-fixed cells. After a wash in PBS,
5  105 cells were fixed in 500 ll of cold 70% ethanol at 4C for at least 2 h.
The cells were then centrifuged, washed once in PBS, resuspended in 500 ll
PBS and incubated in the dark at room temperature for 30 min in the presence
of 100 lg/ml RNAse and 20 lg/ml PI (Sigma Chemicals). The PI fluorescence
of individual nuclei was measured using a FACScan (Becton-Dickinson, San
Jose`, CA). The proportions of cells in the G0/G1, S and G2/M phases of the cell
cycle were automatically calculated by the Lysis II analysis software (Becton-
Dickinson).
Statistical analysis
The results were expressed as means ± standard deviations of three or more
experiments performed in duplicate. Statistical analysis was performed by
using the two-tailed Student’s t-test for unpaired data.
Results
PLC-b2 expression positively correlates with malignant features of
breast cells
We have previously demonstrated that PLC-b2 is weakly expressed in
healthy mammary tissue and more abundant in tumor samples (20). In
particular, the staining intensity increase in parallel with tumorigenic
features, defined as final grade, of cancer samples, as summarized in
the Table I.
Figure 1A, illustrating an immunohistochemical analysis per-
formed with an anti-PLC-b2 antibody on normal breast tissues and
breast tumors with different tumorigenic characteristics, demonstrates
that grade 1 tumors, showing a partially differentiated phenotype,
react poorly, whereas the highly undifferentiated grade 3 tumors ex-
press the largest amount of the enzyme.
Immunochemical analysis with an anti-PLC-b2 antibody was per-
formed on the non-transformed breast-derived cell line (MCF10A)
and on three breast cancer-derived cell lines (MCF7, BT-474
and MDA-MB-231) with different tumoral features. As reported in
Figure 1B, a low amount of PLC-b2 is present in immortalized non-
transformed, highly proliferating MCF10A cells. On the other hand,
cancer-derived cells express this PLC isozyme at levels that positively
correlate with their tumoral characteristics. In fact, small amounts of
PLC-b2 were found in the low-tumorigenic MCF7 and BT-474 cell
lines, which show modest proliferation rate and invasiveness, com-
pared with the elevated amount of protein expressed by the highly
tumorigenic MDA-MB-231 cells, characterized by a faster growth
and an elevated invasive potential.
The correspondence between levels of PLC-b2 and tumorigenic
potential in both tissues and breast-derived cells corroborates the
use of the selected cell lines for this study.
PLC-b2 promotes migration of breast cancer-derived cell lines
Since, as we have reported above, the amount of PLC-b2 in breast-
derived cells correlates with their malignancy, we have investigated if
this protein is involved in promoting and/or modifying some tumor-
related events. For this purpose, cell proliferation and metastatic
potential were investigated in all breast-derived cell lines in which
PLC-b2 expression was negatively modulated by silencing its mRNA
(Figure 2A) or increased by transient transfection with a plasmid
containing the full-length cDNA of human PLC-b2 linked with the
EGFP-cDNA (Figure 2B). As reported in Figure 2C, neither down-
modulation nor over-expression of PLC-b2 significantly affected the
proliferation rate of both non-transformed and tumoral cell lines. On
the other hand, negative and positive modulation of PLC-b2 expres-
sion did not influence the very low motility of MCF10A and BT-474
cells, but induced significant modifications of the migration capability
of cell lines displaying an intrinsic potential to migrate toward a che-
moattractant (Figure 2D). In particular, the reduced expression of
PLC-b2 resulted in a significant inhibition of MDA-MB-231 cell
migration, whereas the over-expression of the protein increased the
motility of both MCF7 and MDA-MB-231 cell lines, particularly of
the highly tumorigenic cells (Figure 2D).
We have then evaluated if modulation of PLC-b2 expression
may influence the invasion capability since cell movement is a prereq-
uisite for cancer invasion and metastasis. As shown in Figure 2E, both
down-modulation and over-expression of the protein did not modify the
ability of the non-tumorigenic MCF10A and of the low-tumorigenic
BT-474 to invade through Extracellular Matrix-coated porous filters
in response to a chemochinetic stimulus. On the contrary, the over-
expression of PLC-b2 did not induce changes of the invasive potential
of MCF7 and MDA-MB-231 cells, whereas down-modulation of
PLC-b2 induces a large decrease in the invasiveness of both malignant
cell lines, particularly evident in the highly tumorigenic cells.
The amount of PLC-b2 increases during progression of cells along the
S and G2/M phases of the cell cycle
Immunocytochemical analysis with an anti-PLC-b2 antibody was
performed on glass slide growing cells. The results, shown in Figure
3A, confirmed the immunochemical data, since cell staining intensity,
indicating the protein amount, was progressively higher starting from
the non-transformed MCF10A to the highly invasive MDA-MB-231
cells. In all cell lines, the highest levels of PLC-b2 were found in the
late phases of the mitotic division. The specificity of the anti- PLC-b2
antibody was demonstrated by performing immunocytochemical
analysis in the presence of the specific blocking peptide (Figure 3B).
To determine the amount of PLC-b2 in the different phases of the
cell cycle, a bi-parametrical analysis of PLC-b2 expression in cells
with different DNA content was performed. The results, reported in
Figure 4A, show a significant increase of PLC-b2 expression during
the progression of cells from G0/G1 to S and G2/M phases of the cell
cycle, particularly evident in the more tumorigenic MCF7 and MDA-
MB-231 cells.
As reported in Figure 4B, the cytofluorimetric determination of
PLC-b2 on the whole-cell population confirmed the immunochemical
results, showing that the highly invasive MDA-MB-231 contains the
largest amount of this protein. The same analysis performed on cells
grown on a serum-deprived mediun confirms the correlation between
PLC-b2 expression and specific phases of cell cycle. In particular,
serum-starved cells that accumulate in the G0/G1 phases show
Table I. Expression of PLC-b2 in breast tissue positively correlates with
malignancy of invasive breast cancers
Features Negative
(%)
Weak
staining (%)
Moderate
staining (%)
Strong
staining (%)
P
Normal tissues 20.0 80.0 0.0 0.0
Breast tumors ,0.001
Final grade 1 18.2 54.5 9.1 18.2
Final grade 2 0.0 16.1 71.0 12.9
Final grade 3 0.0 0.0 17.4 82.6
Tissue microarrays containing 10 samples from normal breast tissues and 77
from invasive breast cancers were subjected to immunohistochemical
analysis with an anti-PLC-b2 antibody and the staining intensity was
estimated on a four-step scale by means of Adobe Photoshop analysis of
acquired images. Tumors were categorized according to arbitrarily defined
criteria into four groups, including completely negative (no staining at all),
weak (staining intensity  100 000 pixel), moderate (staining .100 000, 
200 000 pixel) and strong (staining .200 000 pixel). The staining
corresponding to protein levels was then correlated with final grade of the
different tumors (20).
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a significantly reduced expression of PLC-b2 in comparison with
whole-serum growing cells (Figure 4B).
PLC-b2 induces accumulation of the cells in the G2/M phases of the
cell cycle without modifying cell cycle-related enzymes
On the basis of the above reported findings, suggesting that an in-
creased expression of PLC-b2 takes place during DNA synthesis and
cell mitosis, a further set of experiments was aimed at assessing
whether the modulation of PLC-b2 expression is capable of inducing
changes in cell cycle profile.
As shown in Figure 5A, no significant modifications of the number
of the MCF10A, BT-474 and MCF7 cells in the different phases of
cell cycle were observed when PLC-b2 expression was inhibited. On
the contrary, the down-modulation of PLC-b2 induced a significant
accumulation of the highly invasive MDA-MB-231 cells in the G0/G1
phases and a strong reduction of the same cell population in the G2/M
phases.
The over-expression of PLC-b2 induced, in MCF7 and MDA-MB-
231, a significant decrease of the number of cells in G0/G1 and an
increase of cells in G2/M phases, whereas no effects on the number
of cells located in the different phases of the cell cycle were observed
in MCF10A and BT-474 cell lines over-expressing the enzyme
(Figure 5B).
We have also evaluated the effects of a modulated expression of
PLC-b2 on the number of apoptotic cells by means of cytofluorimetric
analysis. As reported in Figure 5A and B, neither down-modulation
nor over-expression of PLC-b2 significantly affected apoptosis, in all
breast-derived cell lines.
To understand the role of PLC-b2 in regulating cell cycle machin-
ery, we then analyzed the expression of proteins that, in breast tumor
cells, are critical for the transition between the different phases of cell
cycle. In particular, immunochemical analysis with antibodies di-
rected against cyclin A, cyclin D1, cyclin D3 and CDK4 were per-
formed on growing non-transformed and tumoral breast-derived cell
lines in which PLC-b2 expression was modulated. As reported in
Figure 5C, with the exception of the non-transformed MCF10A that
does not express cyclin D1, all examined cell cycle-related proteins
are expressed in breast tumor-derived cells, without significant mod-
ifications due to the over-expression or down-modulation of PLC-b2.
Since cytoskeleton is involved in both migration/invasiveness
and progression along cell cycle, the association between PLC-b2
and actin was analyzed in tumor-derived cells. As reported in Figure 6,
the presence of actin in the anti-PLC-b2 immunoprecipitates
was particularly abundant in the more tumorigenic MCF7 and
MDA-MB-231.
Discussion
Most human malignancies have aberrant expression of signal trans-
duction elements that induce a deregulation of critical cellular pro-
cesses like proliferation, differentiation, survival and motility (23).
PLC, a rate-limiting enzyme in the generation of second messengers
in response to a large variety of growth factors and mitogens, is in-
volved in tumorigenic features of a wide variety of tissues (6–12).
In breast cancer, the role of the different PLC isozymes in neo-
plastic transformation is poorly understood. So far, high levels of
PLC-c1 has been found in breast tumor cells in comparison with
normal mammary tissues, and the over-expression of this PLC iso-
zyme has been related to the epidermal growth factor-driven tumor
cell migration and invasiveness (18,24). Also PLC-d4 has been found
to be up-regulated in a relatively low percentage of breast tumors and
its forced expression in low-tumorigenic breast cancer-derived cells
has been observed to enhance their proliferation rate (19).
By means of immunohistochemical analysis on tissue microarrays
composed of breast cancer specimens and normal epithelia, we have
recently demonstrated that PLC-b2, poorly expressed in normal tis-
sues, is up-regulated in tumor cells (20). We have found that the
expression of PLC-b2 correlates strikingly with the aggressive behav-
ior of primary tumors by analyzing the relationship between PLC-b2
levels and biological and clinicopathological factors. In particular,
a shorter relapse-free interval time and an lower overall survival have
been demonstrated in patients whose primary tumors expressed high
levels of PLC-b2, compared with patients whose breast carcinoma
expressed modest levels of the protein (20).
On the basis of the above-mentioned findings, indicating a strong
correlation between PLC-b2 levels and worse prognosis of breast
cancer, we have tried to establish whether this PLC isozyme plays
a role in promoting and/or modifying the malignancy of breast cancer
Fig. 1. PLC-b2 expression correlates with malignancy of breast cancer cells. (A) Immunohistochemical analysis performed with an anti-PLC-b2 antibody on
deparaffinized tissue sections of human healthy and tumoral breast tissues with different histopatological final grade. Magnification: 40. (B) Western Blot
analysis performed with the indicated antibodies on total lysates from different breast-derived cell lines. Densitometric analysis of autoradiograms was performed
and the results were reported as arbitrary units (a.u.). The data are representative of three separate experiments, performed in duplicate.
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cells. With this aim, we have positively and negatively modulated the
expression of PLC-b2 in breast-derived cell lines, and the most reli-
able tumoral characteristic were analyzed. As experimental models,
we have used a breast-derived non-transformed cell line expressing,
as the normal mammary tissue, low levels of the enzyme and three
different breast cancer-derived immortalized cells, in which this en-
zyme is expressed at levels that positively correlate, as in tumor
tissues, with their tumor-related de-differentiated phenotype.
The disturbance in signal transduction pathways often results in
failure of growth control. Since this may cause hyperproliferation
of cells and ultimately cancer, we have first analyzed the role of
PLC-b2 in modulating the proliferation rate of the different cell lines.
Our results failed to show any effects of modulated PLC-b2 expres-
sion on proliferation of both non-transformed and tumoral cell lines.
Accordingly, the basal levels of the enzyme expressed by the different
cell lines do not correlate with their proliferation rate. In particular,
the non-transformed highly proliferating MCF10A cells possess a very
low amount of PLC-b2 if compared with the breast tumor-derived BT-
474, proliferating very slowly. On the other hand, the weakly pro-
liferating BT-474 cells express PLC-b2 at levels significantly higher
than the more rapidly growing MCF7 cells. These data indicate that
PLC-b2 in breast cancer, at variance with other PLC isoforms, like
PLC-c1 and PLC-d4, is not able to accelerate the cell cycle.
Breast cancer starts as a local in situ carcinoma, but it can progress
into an invasive tumor and culminate in metastasis to the lymph nodes
and distant organs with a frequency/localization that depends on the
type of tumor. The ability of cancers to invade and metastasize re-
quires the acquisition of a specific phenotype that enable the cells to
escape from the localized site and reach an ectopic location in which
they may find a favorable growth environment (25). Unfortunately,
a number of recent data have revealed that the portrait of breast
tumors remains stable during progression and that no major changes
appear to explain why a tumor may evolve to the metastatic stage, and
at present, no markers are clearly associated with the progression of
mammary tumors from in situ to invasive (26).
Deregulation of cell motility stimulated by various extracellular
factors seems to be a critical step in tumor progression. This has
focused the attention on initiators of signaling cascades that regulate
tumor cell migration. In this effort, PLC has been shown to function as
a key molecular switch since the members of this family (both c1 and
c2 isoforms) are involved in several aspects of motility regulation
(27–29). In breast cancer, inhibition of both PLC-c1 expression and
activity resulted in loss of growth factor-induced cell motility and
invasiveness (16,18).
Here we have demonstrated that a forced expression of PLC-b2 is
not able to induce a migration capability in non-migrating cells, like
the non-transformed MCF10A and the low-tumorigenic BT-474, but it
is sufficient to strongly increase the motility of the more tumorigenic
MCF7 and MDA-MB-231 cells. Accordingly, a reduced expression of
the enzyme decreases the motility of the most tumorigenic cell lines,
which express high basal levels of PLC-b2. No effects of a reduced
PLC-b2 expression were found on the non-transformed and on the
low-tumorigenic cells regarding the ability of PLC-b2 to modify the
invasive potential of breast-derived cells, whereas the invasive poten-
tial shown by the highly tumorigenic cell lines was largely reduced.
Fig. 2. PLC-b2 is involved in migration and invasiveness of breast cancer-
derived cell lines. Non-transformed and tumoral breast-derived cells were
subjected to RNA interference assay (siRNA) (A) or were transiently
transfected with an EGFP-tagged construct containing the full-length cDNA
of PLC-b2 (EGFP-PLC-b2) (B). Cell lysates were then subjected to Western
Blot analysis to evaluate PLC-b2 expression. b-tubulin content constitutes an
indicator of the loaded proteins. Autoradiograms were analyzed and the
densitometric results were expressed as arbitrary units (a.u.). After down-
modulation and over-expression of PLC-b2, cell proliferation (C), migration
(D) and invasive potential (E) of the different breast-derived cells were
evaluated. Reported results are the means ± standard deviation of three
evaluations. The asterisks indicate statistically significant results.
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On the contrary, an increased expression of PLC-b2 did not induce
invasiveness in non- and low-tumorigenic cells and did not modify the
already elevated invasive ability of the highly tumorigenic cells.
All these data indicate that PLC-b2 does not possess the capability
to induce the modification of breast-derived cells required to assume
an invasive phenotype but, in tumor cells that display an intrinsic
tumorigenic potential, it is part of intracellular mechanisms able to
change their migration/invasiveness aptitude.
By means of immunohistochemical analysis, we have found that in
primary breast tissues PLC-b2 expression correlates with the response
to the monoclonal antibody MIB-1, which reacts with an antigen that
is only present in the nucleus of proliferating cells (20,30). Also in
breast-derived cell lines, PLC-b2 is particularly abundant in cells that
actively proliferate. In particular, both immunocytochemical analysis
and cytofluorimetrical evaluation of the intracellular amount of PLC-
b2 demonstrated that this protein accumulates in cells that are in the
S/G2/M phases of the cell cycle. We have also found that a forced
expression of PLC-b2 is able to induce an accumulation of tumoral
breast-derived cells in the G2/M phases of the cell cycle and that
a reduced expression of PLC-b2 in cells that show high basal level
of this protein induced an accumulation of cells in the G0/G1 phases.
Breast cancer, as other neoplasia, shows alterations in cellular pro-
teins that regulate the transition through the different phases of the cell
cycle. In this context, a particular significance is displayed by cyclin
D1. In addition to playing a role as a critical modulator of the G1/S
transition, it seems to be important in the loss of proliferative control
during mammary oncogenesis in a way not mediated through regula-
tion of its cyclin-dependent kinase activity (31). Also cyclin D3 plays
a critical role in mammary tumorigenesis and seems to activate an
oncogenic pathway in mammary epithelial cells that is distinct from
that induced by cyclin D1 (32). All D cyclins were shown to bind the
cyclin-dependent kinase CDK4 that is over-expressed in a significant
fraction of breast cancers and seems to be essential for breast tumor-
igenesis (33).
Fig. 3. PLC-b2 expression is highest in the late mitotic stages. Immunocytochemical analysis of PLC-b2 expression was performed on non-transformed and
tumoral breast-derived cell lines (A). The specificity of the antibody was assayed by performing the same experiment in the presence of the blocking peptide (B).
The nuclear morphology was detected by specific staining of DNA with 4#,6-diamidino-2-phenylindole (magnification 100). The arrows indicate cells that are in
the late mitotic stages.
Fig. 4. The amount of PLC-b2 increases during progression of cells along
the S and G2/M phases of the cell cycle. Cytofluorimetric analysis of PLC-b2
expression was performed in cells that are in the different phases of cell cycle
(A) and in breast-derived cell lines growing in control conditions or in
a serum-deprived medium (B). The data, representative of three separate
experiments performed in duplicate, are reported as MFI ratio ± standard
deviation. The asterisks indicate statistically significant results.
PLC-b2 in breast tumor malignancy
1643
 at U
niversita degli Studi di Ferrara- Biblioteca S. M
aria delle G
razie on M
arch 8, 2012
http://carcin.oxfordjournals.org/
D
ow
nloaded from
 
Here we demonstrate that in both non-transformed and tumoral
breast-derived cells, modulated expression of PLC-b2 did not modify
the expression of cyclin D1, cyclin D3 and of their partner CDK4,
as well as of cyclin A, that regulates the transition along the S/G2/M
phases and whose transcription is dependent on the D cyclins activity
(32). This suggests that a role in regulating cyclin-related enzymes
in breast-derived cells may be excluded for PLC-b2. This in contrast
to PLC-b1, which appears to regulate the cell cycle of murine
Fig. 5. PLC-b2 accumulates cells in G2/M without modifying cell cycle-related enzymes. Breast-derived cell lines in which PLC-b2 was either silenced (A) or
over-expressed (B) were subjected to analysis of cell cycle distribution and immunochemical analysis of the indicated cell cycle-related molecules (C). The results
are representative of three independent experiments performed in duplicate. The asterisks indicate statistically significant results. In (D), immunochemical analysis
with the indicated antibodies was performed on anti-PLC-b2 immunoprecipitates. Densitometric analysis of autoradiograms was performed and the results were
reported as arbitrary units (a.u.). The data are representative of three separate experiments, performed in duplicate.
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erythroleukemia cells by acting on the cyclin D3–CDK4 complex
(14).
All the above reported data suggest that PLC-b2 plays a role in
transduction mechanisms responsible for the modifications of cell
morphology required for cell motility, DNA synthesis and mitosis
of breast-derived tumor cells. Concerning the mechanism involved,
it is well documented that phosphoinositides, and particularly PtdIns
(4,5)P2, the preferred substrate of PLC-b2, regulate the activity of
actin-binding proteins during cytoskeleton changes leading to migra-
tion (34), according to the consolidated evidence that the amount of
cytoskeleton-associated phosphoinositides may have a crucial role in
the development of human diseases (15,35–37).
Here, we demonstrate the association between PLC-b2 and the
actin component of cytoskeleton, particularly evident in the more
invasive cell lines. These preliminary data suggest that the altered
levels of PLC-b2 expressed in breast tumor cells may affect the
amount of PtdIns(4,5)P2, responsible, in turn, of deregulated control
of actin cytoskeleton during cell motility and invasion. Similarly, the
large amount of PLC-b2 found in dividing cells also suggests that
PLC-b2 plays a role in regulating the phosphoinositide-related
changes of cytoskeleton architecture that occur during mitosis.
Even though we have not been able to demonstrate a clear role of
PLC-b2 in breast carcinogenesis, this work reports for the first time
a role of this enzyme in promoting some malignant features that allow
breast cancer progression. Since breast tumor phenotype does not
appear to change extensively during tumor evolution from in situ to
invasive carcinoma, molecularly based approaches targeted at specific
factors, including components of the cell signaling mechanism, can
play a crucial role in the early detection and in monitoring the evo-
lution of breast cancer. In this context, PLC-b2 constitutes an indica-
tor of the tumor stage, useful to predict its progression to invasiveness,
metastasis and recurrence and a potential specific target for future
therapeutic strategies of mammary carcinomas.
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